Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

NCT02009449 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02009449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02009449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
November 15, 2013
Completion date
July 22, 2023
Enrollment
353 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal carcinoma, melanoma, non-small cell lung carcinoma, ovarian cancer, pancreatic carcinoma, prostate cancer, renal cell carcinoma, solid tumors